

High Sensitive ELISA Kit for Measuring Human YKL-40

# CircuLex Human YKL-40 ELISA Kit High Sensitivity Version

Cat# CY-8088V2

Intended Use..... 1  
Storage..... 1  
Introduction..... 2  
Principle of the Assay..... 2  
Materials Provided..... 3  
Materials Required but not Provided..... 3  
Precautions and Recommendations..... 4  
Sample Collection and Storage..... 5  
Detailed Protocol..... 6-7  
Calculations..... 8  
Measurement Range..... 8  
Troubleshooting..... 8  
Reagent Stability..... 8  
Assay Characteristics..... 9-12  
Example of Test Results..... 13  
References..... 14-15

## Intended Use

The MBL Research Product **CircuLex Human YKL-40 ELISA Kit High Sensitivity Version (HS Ver.)** is used for the quantitative and high sensitive measurement of human YKL-40 in serum and cell culture supernatant.

Individual users should determine appropriate conditions when using other types of samples.

**This assay kit is for research use only and not for use in diagnostic or therapeutic procedures.**

### Storage

- Upon receipt store all components at 4°C.
- Do not expose reagents to excessive light.

---

## Introduction

---

YKL-40, also called CHI3L1 (chitinase-3-like-1) and human cartilage glycoprotein-39, is a member of the family of mammalian chitinase-like proteins and is a highly conserved protein (1-3). YKL-40 is secreted in vitro by numerous human cancer cell lines of different origin, including glioblastoma, colon cancer, ovarian cancer, prostate cancer, osteosarcoma, malignant melanoma (1-3) as well as by macrophages and neutrophils (9-11). YKL-40 has roles in cell proliferation and differentiation (12), angiogenesis (13-15), inflammation (1-7), remodeling of the extracellular matrix (16,17), and the innate immune response (4). This protein also protects against apoptosis (18).

Increased plasma YKL-40 concentrations have been seen in patients with diseases characterized by inflammation and ongoing tissue remodeling, such as ischemic cardiovascular diseases, cancer, diabetes, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, osteoarthritis, atherosclerosis, inflammatory bowel disease, pneumonia and liver fibrosis (1-8), where they correlate with disease activity (19-21).


---

## Principle of the Assay

---

The MBL Research Product **CircuLex Human YKL-40 ELISA Kit HS Ver.** employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human YKL-40 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and the immobilized antibody binds any human YKL-40 present. After washing away any unbound substances, an HRP conjugated monoclonal antibody specific for human YKL-40 is added to the wells. Following a wash to remove any unbound antibody HRP conjugate, the remaining conjugate is allowed to react with the substrate H<sub>2</sub>O<sub>2</sub>-tetramethylbenzidine. The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured at 450 nm. The absorbance is proportional to the concentration of human YKL-40. A standard curve is constructed by plotting absorbance values versus human YKL-40 concentrations of calibrators, and concentrations of unknown samples are determined using this standard curve.

## Summary of Procedure



---

## Materials Provided

---

All samples and standards should be assayed in duplicate. The following components are supplied and are sufficient for the one 96-well microplate kit.

**Microplate:** One microplate supplied ready to use, with 96 wells (12 strips of 8-wells) in a foil, zip-lock bag with a desiccant pack. Wells are pre-coated with anti-human YKL-40 monoclonal antibody as a capture antibody.

**10X Wash Buffer:** One bottle containing 100 mL of 10X buffer containing Tween®-20

**Dilution Buffer:** One bottles containing 50 mL of 1X buffer use for standard and sample dilution. Ready to use.

**Human YKL-40 Standard:** One vial containing X\* ng of lyophilized recombinant human YKL-40  
**\*The amount is changed depending on lot. See the real "User's Manual" included in the kit box.**

**HRP conjugated Detection Antibody:** One bottle containing 12 mL of HRP (horseradish peroxidase) conjugated anti-human YKL-40 monoclonal antibody. Ready to use.

**Substrate Reagent:** One bottle containing 20 mL of the chromogenic substrate, tetra-methylbenzidine (TMB). Ready to use.

**Stop Solution:** One bottle containing 20 mL of 1 N H<sub>2</sub>SO<sub>4</sub>. Ready to use.

---

## Materials Required but not Provided

---

- **Pipettors:** 2-20 µL, 20-200 µL and 200-1,000 µL precision pipettors with disposable tips.
- **Precision repeating pipettor**
- **Orbital microplate shaker**
- **Microcentrifuge and tubes** for sample preparation.
- **Vortex mixer**
- **(Optional) Microplate washer:** Manual washing is possible but not preferable.
- **Plate reader** capable of measuring absorbance in 96-well plates at dual wavelengths of 450 nm/540 nm. Dual wavelengths of 450/550 or 450/595 nm can also be used. The plate can also be read at a single wavelength of 450 nm, which will give a somewhat higher reading.
- **(Optional) Software package facilitating data generation and analysis**
- **500 or 1,000 mL graduated cylinder.**
- **Reagent reservoirs**
- **Deionized water of the highest quality**
- **Disposable paper towels**

---

## Precautions and Recommendations

---

- **Although we suggest to conduct experiments as outlined below, the optimal experimental conditions will vary depending on the parameters being investigated, and must be determined by the individual user.**
- Allow all the components to come to room temperature before use.
- All microplate strips that are not immediately required should be returned to the zip-lock pouch, which must be carefully resealed to avoid moisture absorption.
- Do not use kit components beyond the indicated kit expiration date.
- Use only the microtiter wells provided with the kit.
- Rinse all detergent residue from glassware.
- Use deionized water of the highest quality.
- Do not mix reagents from different kits.
- The buffers and reagents in this kit may contain preservatives or other chemicals. Care should be taken to avoid direct contact with these reagents.
- Do not mouth pipette or ingest any of the reagents.
- Do not smoke, eat, or drink when performing the assay or in areas where samples or reagents are handled.
- Dispose of tetra-methylbenzidine (TMB) containing solutions in compliance with local regulations.
- Avoid contact with Substrate Solution which contains hydrogen peroxide.
- **CAUTION: Biological samples may be contaminated with infectious agents. Do not ingest, expose to open wounds or breathe aerosols. Wear protective gloves and dispose of biological samples properly.**
- **CAUTION: Stop Solution is a strong acid. Wear disposable gloves and eye protection when handling the solution.**

---

## Sample Collection and Storage

---

**Serum:** Use a serum separator tube and allow samples to clot for  $60 \pm 30$  minutes. Centrifuge the samples at 4°C for 10 minutes at 1,000 x g. Remove serum and assay immediately or store samples on ice for up to 6 hours before assaying. Aliquots of serum may also be stored at below -70°C for extended periods of time. Avoid repeated freeze-thaw cycles.

**Other biological samples:** MBL has not tested.

(e.g. Remove any particulates by centrifugation and assay immediately or aliquot and store samples at below -70°C. Avoid repeated freeze-thaw cycles. Individual users should determine appropriate conditions when using other types of samples.)

---

## Detailed Protocol

---

The MBL Research Product **CircuLex Human YKL-40 ELISA Kit HS Ver.** is provided with removable strips of wells so the assay can be carried out on separate occasions using only the number of strips required for the particular determination. Since experimental conditions may vary, an aliquot of the standard within the kit should be included in each assay as a calibrator. Disposable pipette tips and reagent troughs should be used for all liquid transfers to avoid cross-contamination of reagents or samples.

### Preparation of Working Solutions

All reagents need to be brought to room temperature prior to the assay. Assay reagents are supplied ready-to-use, with the exception of **10X Wash Buffer** and **Human YKL-40 Standard**.

1. Prepare a working solution of **Wash Buffer** by adding 100 mL of the **10X Wash Buffer** to 900 mL of deionized (distilled) water (**ddH<sub>2</sub>O**). Mix well. Store at 4°C for two weeks or -20°C for long-term storage.
2. Reconstitute **Human YKL-40 Standard** with **X\* mL** of **ddH<sub>2</sub>O** by gently mixing. After reconstitution, immediately dispense it in small aliquots (e.g. 100 µL) to plastic micro-centrifuge tubes and store below -70°C to avoid non-specific adsorption to glass surface and multiple freeze-thaw cycles. The concentration of the human YKL-40 in vial should be **19.2 ng/mL**, which is referred to as a **Master Standard** of human YKL-40.

**\*The amount is changed depending on lot. See the real "User's Manual" included in the kit box.**

Prepare Standard Solutions as follows:

Use the **Master Standard** to produce a dilution series (below). Mix each tube thoroughly before the next transfer. **Std.1 (192 pg/mL)** serves as the highest standard. The **Dilution Buffer** serves as the zero standard (Blank).

	Volume of Standard	Dilution Buffer	Concentration
Std.1	10 µL of Master Standard (19.2 ng/mL)	990 µL	192 pg/mL
Std.2	300 µL of Std. 1 (192 pg/mL)	300 µL	96 pg/mL
Std.3	300 µL of Std. 2 (96 pg/mL)	300 µL	48 pg/mL
Std.4	300 µL of Std. 3 (48 pg/mL)	300 µL	24 pg/mL
Std.5	300 µL of Std. 4 (24 pg/mL)	300 µL	12 pg/mL
Std.6	300 µL of Std. 5 (12 pg/mL)	300 µL	6 pg/mL
Std.7	300 µL of Std. 6 (6 pg/mL)	300 µL	3 pg/mL
Blank	-	300 µL	0 pg/mL

**Note:** Do not use a Repeating pipette. Change tips for every dilution. Wet tip with Dilution Buffer before dispensing. Discard any unused Standard Solutions after use.

### Sample Preparation

Dilute samples with **Dilution Buffer**.

- Serum samples may require a 1,000-fold dilution.
- Cell culture supernatants require appropriate dilutions.

## Assay Procedure

1. Remove the appropriate number of microtiter wells from the foil pouch and place them into the well holder. Return any unused wells to the foil pouch, refold, seal with tape and store at 4°C.
2. Dilute serum sample with **Dilution Buffer**. (See "Sample Preparation" above.)
3. Pipette **100 µL** of **Standard Solutions (Std1-Std7, Blank)** and **diluted samples** in duplicates, into the appropriate wells.
4. Incubate the plate at room temperature (ca.25°C) for 60 minutes, shaking at ca. 300 rpm on an orbital microplate shaker.
5. Wash 4-times by filling each well with Wash Buffer (350 µL) using a squirt bottle, multi-channel pipette, manifold dispenser or microplate washer.
6. Add **100 µL** of **HRP conjugated Detection Antibody** into each well.
7. Incubate the plate at room temperature (ca.25°C) for 60 minutes, shaking at ca. 300 rpm on an orbital microplate shaker.
8. Wash 4-times by filling each well with Wash Buffer (350 µL) using a squirt bottle, multi-channel pipette, manifold dispenser or microplate washer.
9. Add **100 µL** of **Substrate Reagent** to each well. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminum foil is recommended. Return Substrate Reagent to 4°C immediately after the necessary volume is removed
10. Incubate the plate at room temperature (ca.25°C) for 10-20 minutes, shaking at ca. 300 rpm on an orbital microplate shaker. The incubation time may be extended up to 30 minutes if the reaction temperature is below than 20°C.
11. Add **100 µL** of **Stop Solution** to each well in the same order as the previously added Substrate Reagent.
12. Measure absorbance in each well using a spectrophotometric microplate reader at dual wavelengths of 450/540 nm. Dual wavelengths of 450/550 or 450/595 nm can also be used. Read the microplate at 450 nm if only a single wavelength can be used. Wells must be read within 30 minutes of adding the Stop Solution.

**Note-1:** Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.

**Note-2:** Reliable standard curves are obtained when either O.D. values do not exceed 0.25 units for the blank (zero concentration), or 3.0 units for the highest standard concentration.

**Note-3:** If the microplate reader is not capable of reading absorbance greater than the absorbance of the highest standard, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine the concentration of off-scale samples. The readings at 405 nm should not replace the on-scale readings at 450 nm.

---

## Calculations

---

Average the duplicate readings for each standard, control and sample, and subtract the optical density of the average zero standard. Plot the optical density versus the concentration of standards and draw the best curve. Most microtiter plate readers perform automatic calculations of analyte concentration. The standard curve fits best to a sigmoidal four-parameter logistic equation. The results of unknown samples can be calculated with any computer program having a four-parameter logistic function.

A standard curve is also to be constructed by plotting the absorbance (Y) versus log of the known concentration (X) of standards, using a cubic function. Alternatively, the logit log function can be used to linearize the standard curve (i.e. logit of optical density (Y) is plotted versus log of the known concentration (X) of standards). To determine the concentration of each sample, first find the optical density on the y-axis and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the x-axis and read the corresponding concentration.

If the samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

---

## Measurement Range

---

The measurement range is 3 pg/mL to 192 pg/mL. Any sample reading higher than the highest standard should be diluted with Dilution Buffer in higher dilution and re-assayed. Dilution factors need to be taken into consideration in calculating the human YKL-40 concentration.

---

## Troubleshooting

---

1. All samples and controls should be assayed in duplicate, using the protocol described in the **Detailed Protocol**. Incubation times or temperatures significantly different from those specified may give erroneous results.
2. Poor duplicates, accompanied by elevated values for wells containing no sample, indicate insufficient washing. If all instructions in the **Detailed Protocol** were followed accurately, such results indicate a need for washer maintenance.
3. Overall low signal may indicate that desiccation of the plate has occurred between the final wash and addition of Substrate Reagent. Do not allow the plate to dry out. Add Substrate Reagent immediately after wash.

---

## Reagent Stability

---

All of the reagents included in the MBL Research Product **CircuLex Human YKL-40 ELISA Kit HS Ver.** have been tested for stability. Reagents should not be used beyond the stated expiration date.

---

## Assay Characteristics


---

### 1. Sensitivity

The limit of detection (defined as such a concentration of human YKL-40 giving absorbance higher than mean absorbance of blank\* plus three standard deviations of the absorbance of blank in 24 assays) is better than 1.22 pg/mL of sample.

\* Dilution Buffer was pipetted into blank wells.

Typical standard curve



## 2. Precision

### Intra-assay Precision (Precision within an assay)

Three samples\* of known concentration were tested sixteen times on one plate to assess intra-assay precision.

- Intra-assay (Within-Run, n=16) CV=5.1, 2.0, 4.3 %

\* Sample 1: HL-60 cells' culture sup.(1:1.5)  
 Sample 2: DLD1 cells' culture sup.(1:8)  
 Sample 3: THP-1 cells' culture sup.(1:250)

**Human YKL-40 conc. (pg/mL)**

	Sample 1	Sample 2	Sample 3
1	41.03	100.46	142.37
2	38.67	99.31	137.31
3	40.14	95.07	140.90
4	39.02	98.87	142.27
5	40.02	101.01	129.73
6	41.10	100.13	141.38
7	40.14	96.28	150.35
8	41.91	100.68	138.17
9	36.94	103.37	142.87
10	36.66	101.21	139.42
11	35.64	97.63	144.41
12	35.61	98.80	143.89
13	38.82	100.20	147.71
14	37.06	101.23	141.12
15	37.87	99.33	145.64
16	37.79	99.69	157.89
<b>MAX.</b>	<b>41.91</b>	<b>103.37</b>	<b>157.89</b>
<b>MIN.</b>	<b>35.61</b>	<b>95.07</b>	<b>129.73</b>
<b>MEAN</b>	<b>38.65</b>	<b>99.58</b>	<b>142.84</b>
<b>S.D.</b>	<b>1.96</b>	<b>2.01</b>	<b>6.13</b>
<b>C.V.</b>	<b>5.1%</b>	<b>2.0%</b>	<b>4.3%</b>

Inter-assay Precision (Precision between assays)

Three samples\* of known concentration were tested in five separate assays to assess inter-assay precision.

- Inter-assay (Run-to-Run, n=5) CV= 7.2, 2.7, 4.1 %


\* Sample 1: HL-60 cells' culture sup.(1:1.5)  
 Sample 2: DLD1 cells' culture sup.(1:8)  
 Sample 3: THP-1 cells' culture sup.(1:250)

	<b>Human YKL-40 conc. (pg/mL)</b>		
	<b>Sample 1</b>	<b>Sample 2</b>	<b>Sample 3</b>
1	34.68	82.57	123.74
2	29.00	82.74	113.76
3	32.04	85.54	111.53
4	29.62	79.37	116.51
5	32.36	83.18	119.10
<b>MAX.</b>	<b>34.68</b>	<b>85.54</b>	<b>123.74</b>
<b>MIN.</b>	<b>29.00</b>	<b>79.37</b>	<b>111.53</b>
<b>MEAN</b>	<b>31.54</b>	<b>82.68</b>	<b>116.93</b>
<b>S.D.</b>	<b>2.29</b>	<b>2.20</b>	<b>4.76</b>
<b>C.V.</b>	<b>7.2%</b>	<b>2.7%</b>	<b>4.1%</b>

### 3. Linearity

To assess the linearity of the assay, three samples\* were serially diluted with Dilution Buffer to produce samples with values within the dynamic range of the assay.

\* Sample 1: HL-60 cells' culture sup.  
Sample 2: DLD1 cells' culture sup.  
Sample 3: THP-1 cells' culture sup.




---

### Example of Test Results

---

Fig. Human YKL-40 concentration in healthy Japanese volunteers' sera (n=30) and type II diabetes patients' sera (n=20)



---

## References

---

1. Johansen JS *et al.* Serum YKL-40, a new prognostic biomarker in cancer patients? *Cancer Epidemiol Biomarkers Prev.* 2006 Feb;15(2):194-202.
2. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. *Dan Med Bull.* 2006 May;53(2):172-209.
3. Bussink AP *et al.* Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. *Genetics.* 2007 Oct;177(2):959-70.
4. Chupp GL *et al.* A chitinase-like protein in the lung and circulation of patients with severe asthma. *N Engl J Med.* 2007 Nov 15;357(20):2016-27.
5. Létuvé S *et al.* YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. *J Immunol.* 2008 Oct 1;181(7):5167-73.
6. Kastrup J *et al.* High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. *Eur Heart J.* 2009 May;30(9):1066-72.
7. Johansen JS *et al.* Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. *J Clin Oncol.* 2009 Feb 1;27(4):572-8.
8. Nielsen AR *et al.* Plasma YKL-40: a BMI-independent marker of type 2 diabetes. *Diabetes.* 2008 Nov;57(11):3078-82.
9. Rehli M *et al.* Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. *Genomics.* 1997 Jul 15;43(2):221-5.
10. Boot RG *et al.* Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. *Arterioscler Thromb Vasc Biol.* 1999 Mar;19(3):687-94.
11. Volck B *et al.* YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. *Proc Assoc Am Physicians.* 1998 Jul-Aug;110(4):351-60.
12. Johansen JS *et al.* YKL-40 protein expression in the early developing human musculoskeletal system. *J Histochem Cytochem.* 2007 Dec;55(12):1213-28.
13. Nishikawa KC and Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. *Exp Cell Res.* 2003 Jul 1;287(1):79-87.
14. Saidi A *et al.* Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. *Int J Cancer.* 2008 May 15;122(10):2187-98.
15. Shao R *et al.* YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. *Oncogene.* 2009 Dec 17;28(50):4456-68. doi: 10.1038/onc.2009.292.

16. Recklies AD *et al.* The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. *Biochem J.* 2002 Jul 1;365(Pt 1):119-26.
17. Ling H and Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. *Biochem J.* 2004 Jun 15;380(Pt 3):651-9.
18. Lee CG *et al.* Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. *J Exp Med.* 2009 May 11;206(5):1149-66.
19. Johansen JS *et al.* Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. *Br J Rheumatol.* 1996 Jun;35(6):553-9.
20. Johansen JS *et al.* S A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. *Br J Rheumatol.* 1993 Nov;32(11):949-55.
21. Kucur M *et al.* Serum YKL-40 levels in patients with coronary artery disease. *Coron Artery Dis.* 2007 Aug;18(5):391-6.

For more information, please visit our web site.

<https://ruo.mbl.co.jp/>

#### MANUFACTURED BY

**MBL** A JSR Life Sciences Company  
MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

URL: <https://ruo.mbl.co.jp>

E-mail: [support@mbi.co.jp](mailto:support@mbi.co.jp)

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from MBL. To inquire about licensing for such commercial use, please contact us via email.